Health
Virus drug benefit only marginal: study – Shepparton News
Moderately ill COVID-19 patients had their condition improve after a 5-day course of Gilead Sciences Inc’s remdesivir but the drug did not significantly shorten hospital stays and a 10-day course did not show a benefit, according to new data.The drug, which was shown in a trial of severely ill COVID-19 patients to shorten their hospital recovery time, has been at the forefront of the battle against the pandemic.The 600-patient analysis, published on Friday by the Journal of the American Medical …
-
Noosa News18 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
Noosa News16 hours agoNo matter what happens in his Origin debut, history beckons for rookie maroon Robert Toia
-
General14 hours agoDairy farmers devastated by floods across parts of New South Wales
-
Noosa News23 hours agoBrisbane news live: Federal fund for council’s cyclone clean-up dries up